Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Imunon › Chair received an award of 3,484 IMNN shares
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date May 22, 2026
Reporting period Not applicable
Filed with the SEC May 27, 2026 Chair Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001437749-26-018566
Filed / recorded
May 27, 2026, 8:22 PM UTC
Added to OQRO Oct 8, 2026, 2:32 AM UTC
Data quality Verified: identifiers matched exactly
Reporting person Michael H Tardugno
Relationship Director, Officer
Officer title Executive Chairman of Board
Table Non-derivative (Table I)
Transaction date May 22, 2026
Acquired / disposed Acquired (A)
Footnotes from the filing Stock granted in lieu of cash for base salary
Around the same time Insider filing
Traded Jun 18 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 18 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 5 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Mar 31, 2026 Company filing · Form 8-K · Results Reported its results May 1, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On May 1, 2026, Imunon, Inc. (the “Company”) entered into change of control agreements (“CIC Agreements”), following approval of the Compensation Committee of the Board of Directors (the “Board”) of the Company with each of Stacy Lindborg, the Company’s Chief Executive Officer and President, Douglas Faller, the Company’s Chief Medical Officer, and Susan Eylward, the Company’s General Counsel and Corporate Secretary,…” May 12, 2026 Company filing · Form 8-K · Results Reported its results What came next Jun 1, 2026 Company filing · Form 8-K · Material agreement, New debt Signed an important agreement, and took on new debt or obligations (and 3 more items) Jun 16, 2026 Company filing · Form 8-K · Executive change, Shareholder vote Changed a top executive or board member, and held a shareholder vote “At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Imunon, Inc. (the “Company”) held on June 16, 2026, the Company’s stockholders approved an amendment to the IMUNON, Inc. 2018 Stock Incentive Plan (the “Plan”), which amendment was approved by the Company’s board of directors on February 27, 2026.” Jun 29, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member
“On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (the “Retirement Date”).”
